Optimizing quality and efficacy of colorectal cancer diagnosis and endoscopic therapy by van de Wetering, Alouisa J.P.
 
 
 
Optimizing quality and efficacy of colorectal cancer
diagnosis and endoscopic therapy
Citation for published version (APA):
van de Wetering, A. J. P. (2020). Optimizing quality and efficacy of colorectal cancer diagnosis and
endoscopic therapy. ProefschriftMaken. https://doi.org/10.26481/dis.20201124aw
Document status and date:
Published: 01/01/2020
DOI:
10.26481/dis.20201124aw
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 07 Jan. 2021
 233
A
VALORIZATION
Colorectal cancer (CRC) is the third leading type of cancer worldwide, among both 
men and women. Since it is known that CRC derives from precursor lesions, detection 
and resection of these precursor lesions leads to a decrease in incidence, morbidity 
and mortality of CRC. With this goal, CRC screening programs have successfully 
been introduced and implemented.1 Patients with an increased risk to develop CRC 
(i.e. post-CRC status, post-polypectomy or familial/genetic risk) enter surveillance 
programs.2
Valorization is described as “the process of creating value from knowledge by 
making knowledge suitable and available for societal and/or economic application by 
transforming it into products, services, processes and new business.”3 
In the framework of this thesis, we identified several steps in the process of CRC 
diagnosis and endoscopic therapy, following the patient journey in order to point 
out specific characteristics, strengths and weaknesses of each step (Table 1), so that 
recommendations can be made for future research and clinical practice. 
By optimizing these steps, value is created through implementation of obtained 
knowledge into clinical practice, hence societal and economic application. 
Pre-selection Which patients should be invited for a colonoscopy and what are the 
best methods to identify patients (with precursor lesions) at risk for 
CRC?
Colonoscopy Invasive tool to detect precursor lesions with the option to resect these 
lesions; How can we make sure that all (relevant) lesions are detected 
and determined? How well is the endoscopist trained and equipped to 
differentiate between the different types of lesions?
Treatment Where surgery used to be the “gold standard” for treatment of CRC, 
a shift occurs towards more advanced endoscopic treatments, that 
potentially are less invasive and have lower complication rates 
compared to surgery. How well can invasive lesions be differentiated 
from non-invasive lesions? And what is the best, less-invasive 
(endoscopic) technique to resect these (non) invasive lesions? 
Surveillance In current practice the surveillance population enters the colonoscopy-
based surveillance program. What are (less invasive) alternative 
surveillance strategies or can intervals for colonoscopy be prolonged?
Table 1. Steps and questions in the process of optimizing quality and efficacy of CRC diagnosis 
and endoscopic therapy.
Valorization
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Value for patients
For patients it is crucial that each of the four steps, described above, is effective and 
of high quality while the burden of each step should be as low as possible. 
In current CRC screening programs, fecal immunochemical testing (FIT) is used for 
pre-selection. Since FIT based preselection is not optimal in detecting precursor 
lesions, it is essential to develop and test other diagnostic tools, where new biomarkers 
could possibly increase sensitivity and specificity and result in a more optimal pre-
selection, so that a better selected group of patients is receiving a colonoscopy. Our 
systematic review (chapter 2) revealed that of the studies addressing diagnostic 
CRC DNA methylation markers, the majority of markers have been studied in tissue, 
which can only be obtained via colonoscopy. Bodily fluids (i.e. blood and stool) can 
be collected with a much lower burden to the patients, since these are less invasive 
to obtain.  In case a minimal invasive test (with high sensitivity and specificity) is 
available, unnecessary (invasive) colonoscopies can be avoided.
     To reach this goal, additional research is needed. For future DNA methylation 
biomarker studies it is important to define the clinical need and intended biomarker 
use before starting the study and to evaluate the current available research and 
the level of evidence. It is important that the specimen and cohort complement 
available evidence and that it is compared to current gold standard methods. This 
way the study adds substantially to the already performed research and can make a 
difference in bringing biomarkers to clinical practice.
Patients with a history of CRC or polypectomy, or familial/genetic risk enter into 
a surveillance program. Current surveillance is fully colonoscopy-based: patients 
receive colonoscopies on regular basis, thereby increasing the patient’s burden. With 
implementation of nationwide CRC screening programs, and the increased quality 
of colonoscopy, the added value of intensive, high frequency colonoscopy-based 
surveillance programs is under debate.  In this thesis we investigated an alternative 
surveillance method, using a multitarget stool DNA (mt-sDNA) test (Cologuard), 
including biomarkers and hemoglobin (MOCCAS study). The interim analysis 
(chapter 6) of that study shows that the mt-sDNA test has a higher sensitivity than
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FIT for precursor lesions in the surveillance population. When a low-test cut-off is 
used in order to reach 50% positivity rate, the mt-sDNA test sensitivity increases 
and the number of unnecessary colonoscopies will be reduced by 50%. This interim 
analysis already shows promising results. After completion of the study, full analyses 
will be performed, and mathematical modelling will be applied to determine the 
optimal stool-based surveillance strategy.   
     Colonoscopy is an invasive procedure, which can be used for both diagnosis and 
treatment. Data from patient reported outcome measures (PROM’s) and patient 
questionnaires show that bowel preparation and post-colonoscopy abdominal 
complaints are perceived as most burdensome by patients undergoing colonoscopy.4
Colonoscopy remains the most important tool for diagnosis of precursor lesions and 
for diagnosis of CRC. Colonoscopy allows us to take biopsies or resect (precursor) 
lesions. Optimization of colonoscopy procedures may help to significantly reduce 
patient burden while not affecting quality and efficacy. 
To optimize the diagnostic process, adequate detection and determination of polyps 
is crucial. We investigated the additional value of image enhancement strategies in 
patients with Lynch Syndrome. These patients have a significantly increased risk 
of developing CRC.  In these patients it is crucial to optimize the detection of the 
precursor lesions, so that development and progression to CRC can be prevented. In 
chapter 3 an overview of current literature was given, where a large heterogeneity 
among study designs was shown. For future research, standardization of study 
designs is needed, with a randomized, cross-over, back-to-back study design as best 
option. Important factors to increase the quality and efficacy of colonoscopy include 
1) use of image-enhancement, 2) training of endoscopists in detection and removal 
of non-polypoid colorectal neoplasms and 3) stricter adherence to surveillance 
intervals. 
The determination and in-vivo estimation of histology (i.e. optical diagnosis), was 
studied in the screening population. Two potential strategies in low-risk, diminutive 
(≤5mm) polyps were investigated, aiming for less resections and saving costs by not 
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sending these polyps for histological evaluation. According to our study (chapter 4), 
the accuracy for optical diagnosis of adenomatous histology is currently too low and 
does not consistently meet the set thresholds (PIVI criteria). Therefore, we are not 
ready to implement these strategies in current daily practice. For implementation of 
optical diagnosis in the CRC screening program, several adjustments need to be done: 
in the reporting of lesions by standard use of optical classification systems and by 
inclusion of the ‘level of confidence’ of the endoscopist performing the colonoscopy. 
Additional endoscopist training in optical diagnosis should be undertaken. Only 
when detection and determination have been optimized, colonoscopy as a diagnostic 
tool will reach optimum diagnostic accuracy and efficacy.
Nowadays, new endoscopic resection techniques are available. With implementation 
of the CRC screening program, more lesions are detected, and more early (T1) CRCs 
are diagnosed. For a subset of T1 CRCs, these less-invasive endoscopic treatments 
are alternative strategies for colorectal surgery. It is of great importance to correctly 
estimate the CRC risk in patients when choosing for the less-invasive treatment 
strategy. In current clinical practice however, only 20.9% of the T1 CRCs were 
recognized as such. Incorrect optical diagnosis results in non-curative endoscopic 
resections, this often leads to salvage surgery, which in a substantial number of 
cases appears to be unnecessary (chapter 5).
Implementation of the validated OPTICAL risk chart provides guidance by estimating 
CRC risk and should therefore be considered for implementation in daily practice.5
Value for society
In 2003, the European Committee advised all countries to implement CRC screening 
programs. After years of study, in 2014 the biannual FIT-based program was 
implemented in the Netherlands.1 In the first years of the program, colonoscopy 
capacity was limited due to a shortage of certified endoscopists and higher 
participation rates than expected.
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Because of the initially limited colonoscopy capacity and high participation rates 
among the population, waiting lists increased for CRC screening and also for 
symptomatic patients. Based on capacity issues, it was decided to increase the FIT 
cut-off value six months after implementation of the screening program. In 2018, 
four years after implementation, nationwide colonoscopy capacity is sufficient to 
accommodate all FIT positive referrals.
With implementation of the CRC screening program, more low-risk (small and 
diminutive) polyps are diagnosed and resected. In this thesis, the implementation 
of cost-effective strategies, i.e. ‘resect and discard’ and ‘diagnose and leave’ 
for diminutive polyps was studied. In case optical diagnosis can be optimized, 
diminutive polyps might be left in place or are resected but not sent in for histology. 
This strategy will result in substantial financial benefit.
        As a consequence of implementation of the CRC screening program, more patients 
will enter colonoscopy-based surveillance programs. This results in a rapidly 
expanding surveillance population, adding substantially to colonoscopy capacity. 
Nowadays more than 25% of colonoscopies is performed for surveillance, while the 
cost-benefit of colonoscopy surveillance is not yet clear. Therefore, it is worthwhile 
to investigate alternative surveillance strategies. Better pre-selection of patients will 
lead to less (unnecessary) colonoscopies, with financial impact.  Furthermore, the 
pressure on colonoscopy capacity will decrease and attention can be given to other 
important health issues in endoscopy practice such as innovation in therapeutic 
endoscopic interventions.
 In the MOCCAS study (MOlecular stool testing for Colorectal CAncer Surveillance), an 
observational cross-sectional study, patients are approached to collect stool samples 
for molecular testing and FIT prior to their scheduled surveillance colonoscopy 
(chapter 6). The currently ongoing study will after completion, be used as input for 
mathematical modelling to find the optimal (stool-based) surveillance strategy. This 
should add to reduction of patient burden and increasing (cost-) effectiveness. 
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Overall and future value
Diagnosing CRC in an early or precursor stage, may lead eventually to prevention 
of CRC. It is worthwhile to take steps to optimize this process, because by early 
diagnosis and treatment significant costs are saved from chemotherapy and surgery.
Steps taken to optimize the process of CRC diagnosis and treatment are of value, 
both for patients as well as society. The future value for each step is shown in Table 2.
Pre-selection Role of diagnostic biomarkers/biomarker panels in the pre-
selection, complementary to the currently used FIT-test.
Colonoscopy Optimal detection and determination of (pre) malignant lesions is 
key. To improve this, endoscopist training is important, as well as 
the potential role of artificial intelligence (AI) for correct optical 
diagnosis. Further research and evidence is needed before AI can be 
used in daily endoscopy practice.6
Treatment Shift from surgical to endoscopic/minimal invasive treatment 
with a personalized plan for every patient/lesion, starting with 
improvement of correct estimation and recognition of early CRCs.
Surveillance Biomarkers may play a role in future surveillance strategies. 
When determining the optimal personalized surveillance strategy, 
several factors, e.g. risk differences in a heterogeneous population, 
should be taken into account.
Table 2. Steps and potential ways for optimizing quality and efficacy of CRC diagnosis and 
endoscopic therapy.
In this thesis several aspects have been explored that may help to optimize quality 
and efficacy of CRC diagnosis and endoscopic therapy. Additional research is needed 
to adequately implement these adjustments in CRC diagnosis and treatment in daily 
practice.  In this respect, costs and quality remain key factors. 
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